Document is current
Any future updates will be listed below
-
Authors
Ronnje, Louise
Länsberg, John-Kalle
Vikhareva, Olga
Hansson, Stefan R.
Herbst, Andreas
Zaigham, Mehreen
-
Funding
Funding for this research was provided by:
Swedish Medical Research Council
Medicinska Fakulteten, Lunds Universitet
- License Information
-
More Information
Article History
Received: 12 May 2020
Accepted: 12 August 2020
First Online: 4 September 2020
Ethics approval and consent to participate
: Ethical approval was not sought due to the nature of the case report. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
: The patient provided written informed consent for the publication of potentially identifying images and clinical details on behalf of themselves and their child.
: The datasets used and analysed during the current study available from the corresponding author on reasonable request.
: A.H. is a board member and shareholder in Amniotics AB, a start-up company developing treatment for severe lung disease in COVID-19. S.R.H. holds patents for the diagnosis and treatment of preeclampsia. S.R.H. is also a co-founder of the company Guard Therapeutics International formerly named A1M Pharma AB (ExternalRef removed).
